SynthesisAnnals of nuclear medicine2026
PSMA PET/CT imaging for biochemical recurrence in prostate cancer: can it replace conventional imaging and guide salvage therapy?
Synthesis in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biochemical recurrence (BCR) after primary treatment for prostate cancer presents a significant clinical challenge. Conventional imaging modalities have limited sensitivity for detecting sites of recurrence, particularly at low prostate specific antigen (PSA) levels. Prostate specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has emerged as a promising diagnostic tool that may transform the management paradigm for recurrent prostate cancer. To systematically evaluate the diagnostic performance of PSMA PET/CT in patients with biochemical recurrence of prostate cancer, compare it with conventional imaging modalities, and assess its impact on salvage therapy decisions. A systematic review was conducted following the PRISMA guidelines. PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2020 and 2025. Studies evaluating PSMA PET/CT in patients with biochemical recurrence after primary treatment were included. The primary outcomes were detection rates stratified by PSA levels, diagnostic accuracy compared to conventional imaging, and the impact on management decisions. PSMA PET/CT demonstrated superior detection rates compared to conventional imaging across all PSA levels, with detection rates ranging from 36.2% to 96.7% for PSA levels below 0.5 ng/mL and above 5 ng/mL, respectively. In patients with negative conventional imaging, PSMA PET/CT identified true positive lesions in 64% of cases (95% CI, 56.7%-71.5%). Among patients with high-risk biochemically recurrent prostate cancer and negative conventional imaging, PSMA PET/CT detected distant metastatic disease (M1) in 46% of patients. Management plans were altered in 54-76% of cases based on PSMA PET/CT findings, with significant implications for salvage therapy targeting. PSMA PET/CT significantly outperforms conventional imaging in detecting sites of recurrence across all PSA levels, with particularly notable advantages at low PSA values. The high detection rates and accuracy of PSMA PET/CT in patients with negative conventional imaging support its role as a replacement for or complement to standard imaging protocols, while acknowledging current limitations in availability, cost, and long-term outcome data. PSMA PET/CT findings frequently alter management decisions, enabling more precise targeting of salvage therapies and potentially improving oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.